Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Code Biotherapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Code Biotherapeutics's investors include New Enterprise Associates, Hatteras Venture Partners, 4BIO Capital, Amgen Ventures, UCB Ventures.
Code Biotherapeutics is headquartered in Hatfield, United States.
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Code Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Code Biotherapeutics — Funding & Investors." VCBacked, June 7, 2022, https://www.vcbacked.co/company/code-biotherapeutics. Accessed July 21, 2026.
VCBacked. (2022). Code Biotherapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/code-biotherapeutics
{{cite web |title=Code Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/code-biotherapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated